KRAS and neoplasm: In case P2, the BRAF p.V600E (c.1799 T > A) mutant allele frequency (29 %) was consistent with the estimated tumor cellularity (41–60 %), suggesting KRAS p.G15S (c.43G > A) was present in a subpopulation of tumor.